Product
Nintedanib
Aliases
BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120 (5 other aliases)
38 clinical trials
40 indications
Indication
HealthyIndication
Lung DiseasesIndication
InterstitialIndication
Healthy SubjectsIndication
Idiopathic Pulmonary FibrosisIndication
Lung CancerIndication
EGFR gene mutationIndication
EGFR-TKI Resistant MutationIndication
systemic sclerosisIndication
Interstitial Lung DiseaseIndication
lung cancerIndication
Non-Small CellIndication
Non Small Cell Lung Cancer MetastaticIndication
Bronchiolitis Obliterans SyndromeIndication
Bronchiolitis ObliteransIndication
MesotheliomaIndication
Fibroblast Growth Factor BasicIndication
FLT3 Internal Tandem DuplicationIndication
Adult Acute Myeloid LeukemiaIndication
Acute Myeloid LeukemiaIndication
Carcinoid TumorIndication
Metastatic Carcinoid TumorIndication
Neuroendocrine TumorIndication
Pancreatic CancerIndication
Hemorrhagic telangiectasiaIndication
Hereditary Hemorrhagic TelangiectasiaIndication
Lung Transplant RecipientsIndication
Cervical CancerIndication
Endometrial CancerIndication
COVID-19 Induced Pulmonary FibrosisIndication
Lung Transplant ComplicationsIndication
Lung MetastasesIndication
advanced solid tumorsIndication
Pulmonary FibrosisIndication
respiratory diseaseIndication
cancerIndication
Non-Small Cell LungIndication
NSCLCClinical trial
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
The Effect of Multiple Oral Doses of BI 1015550 on the Pharmacokinetics of Nintedanib and Pirfenidone Administered Single Dose to Healthy Male Subjects (Open-label, Two-period, Fixed-sequence Crossover Trial)Status: Completed, Estimated PCD: 2023-12-14
Clinical trial
A Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The "INTENSE" StudyStatus: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
An Open Label, Randomised Study in Healthy Participants to Investigate the Effect of AZD5055 on the Pharmacokinetics of Nintedanib.Status: Terminated, Estimated PCD: 2023-07-17
Clinical trial
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in JapanStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 3 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)Status: Active (not recruiting), Estimated PCD: 2025-07-14
Clinical trial
Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Treatment in Patients Suffering From Chronic Fibrosing ILD With a Progressive PhenotypeStatus: Active (not recruiting), Estimated PCD: 2024-04-09
Clinical trial
Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis PatientsStatus: Completed, Estimated PCD: 2021-12-30
Clinical trial
A Regulatory Required Non-interventional Study to Monitor the Safety and Effectiveness of Ofev(Nintedanib 150mg/100mg BID) in Korean PatientsStatus: Completed, Estimated PCD: 2022-08-02
Clinical trial
Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary FibrosisStatus: Completed, Estimated PCD: 2023-07-14
Clinical trial
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in JapanStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung DiseaseStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)Status: Completed, Estimated PCD: 2022-08-30
Clinical trial
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With NintedanibStatus: Completed, Estimated PCD: 2023-02-22
Clinical trial
Relative Bioavailability of 100 mg Nintedanib (Ofev®) Given as Four Capsules of 25 mg Compared to One Capsule of 100 mg Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPFStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase I Study for Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of Nintedanib in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Three Parts)Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in JapanStatus: Completed, Estimated PCD: 2023-05-02
Clinical trial
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-08-27
Clinical trial
Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Multicentre Clinical Trial Evaluating the Safety and Efficacy of the Combination of Nintedanib+Tocilizumab Compared to Standard Treatment in Patients With Systemic Sclerosis and Interstitial Lung Disease. Analysis With Theranostic ApproachStatus: Not yet recruiting, Estimated PCD: 2027-12-30
Clinical trial
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-28
Clinical trial
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II TrialStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer GroupStatus: Active (not recruiting), Estimated PCD: 2024-03-26
Clinical trial
Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Treatment in Patients Suffering From Chronic Fibrosing ILD With a Progressive PhenotypeStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid TumorsStatus: Completed, Estimated PCD: 2019-09-01
Clinical trial
A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic CancerStatus: Terminated, Estimated PCD: 2021-10-26
Clinical trial
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II StudyStatus: Completed, Estimated PCD: 2023-02-24
Clinical trial
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 0p-1-2Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."Status: Active (not recruiting), Estimated PCD: 2021-01-01
Clinical trial
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial CancerStatus: Completed, Estimated PCD: 2021-10-20
Clinical trial
"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"Status: Recruiting, Estimated PCD: 2023-10-11
Clinical trial
Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled TrialStatus: Terminated, Estimated PCD: 2021-12-21
Clinical trial
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation PneumonitisStatus: Completed, Estimated PCD: 2024-04-12
Clinical trial
Phase Ib Trial Of Pembrolizumab And NintedanibStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Early Nintedanib Deployment in COVID-19 Interstitial Lung DiseaseStatus: Completed, Estimated PCD: 2024-02-01
Clinical trial
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2020-01-09